Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells

Abstract Objective The current standard treatment for ovarian carcinoma, consisting of surgery followed by chemotherapy with carboplatin and paclitaxel, is fraught with a high rate of recurrences. We hypothesized that targeted inhibition of specific signaling pathways in combination with conventiona...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2009-09, Vol.114 (3), p.516-522
Hauptverfasser:	Schlosshauer, Peter W, Li, Wei, Lin, Kai-Ti, Chan, Joseph L.-K, Wang, Lu-Hai
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis - drug effects Carboplatin Carboplatin - administration & dosage Cell Growth Processes - drug effects Cell Line, Tumor Chemotherapy Chromones - administration & dosage Chromones - pharmacology Drug Synergism Female Hematology, Oncology and Palliative Medicine Humans Mechanistic Target of Rapamycin Complex 1 Morpholines - administration & dosage Morpholines - pharmacology Multiprotein Complexes Obstetrics and Gynecology Oncogene Protein v-akt - antagonists & inhibitors Oncogene Protein v-akt - biosynthesis Oncogene Protein v-akt - metabolism Ovarian carcinoma Ovarian Neoplasms - drug therapy Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphatidylinositol 3-Kinases - metabolism Phosphatidylinositols - administration & dosage Phosphatidylinositols - pharmacology PI3 kinase Proteins Rapamycin Signal Transduction - drug effects Sirolimus - administration & dosage Sirolimus - pharmacology TOR Serine-Threonine Kinases Transcription Factors - antagonists & inhibitors Transcription Factors - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!